A simple and sensitive HPLC fluorescence method for determination of tadalafil in mouse plasma

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 878, Issue 28, 2010, Pages 2891-2895

  Farthing, Christine A ^a   Farthing, Don E ^a   Koka, Saisudha ^b   Larus, Terri ^a   Fakhry, Itaf ^a   Xi, Lei ^b   Kukreja, Rakesh C ^b   Sica, Domenic ^a   Gehr, Todd W B ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Doxorubicin; Fluorescence; HPLC; Monolithic column; Tadalafil

Indexed keywords

CARDIOPROTECTIVE EFFECT; CHEMOTHERAPEUTIC DRUGS; DETECTION LIMITS; DOXORUBICIN; EMISSION WAVELENGTH; EXCITATION WAVELENGTH; FLUORESCENCE DETECTION; FLUORESCENCE METHOD; HPLC; INTERNAL STANDARDS; MOBILE PHASE; MONOLITHIC COLUMNS; MOUSE HEART; MOUSE PLASMA; PHOSPHODIESTERASES; PROTEIN PRECIPITATION; RELATIVE STANDARD DEVIATIONS; SAMPLE PREPARATION; TADALAFIL; TRIFLUOROACETIC ACIDS;

ACETONITRILE; DEIONIZED WATER; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

PLASMAS;

ACETONITRILE; DOXORUBICIN; SODIUM CHLORIDE; TADALAFIL; TRIFLUOROACETIC ACID;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; FLOW RATE; FLUORESCENCE ANALYSIS; HEART PROTECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PH MEASUREMENT; PRECIPITATION; PRIORITY JOURNAL;

ANIMALS; CARBOLINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOXORUBICIN; DRUG STABILITY; LINEAR MODELS; MALE; MICE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOLUBILITY; SPECTROMETRY, FLUORESCENCE;

EID: 77957322337     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2010.07.022     Document Type: Article

References (18)

1. Gresser U., Gleiter C.H. Eur. J. Med. Res. 2002, 7:435.
2. Forgue S.T., Patterson B.E., Bedding A.W., Payne C.D., Phillips D.L., Wrishko R.E., Mitchell M.I. Br. J. Clin. Pharmacol. 2005, 61:280.
3. Curran M.P., Keating G.M. Drugs 2003, 63:2203.
4. Giuliano F., Varanese L. Eur. Heart J. Suppl. 2002, 4(Supplement H):H24.
5. Singh S., Prasad B., Savaliya A.A., Shah R.P., Gohil V.M., Kaur A. Trends Anal. Chem. 2009, 28:13.
6. Lue T.F. N. Eng. J. Med. 2000, 342:1802.
7. Swain S.M., Whaley F.S., Ewer M.S. Cancer 2003, 97:2869.
8. Ramakrishna N.V.S., Vishwottam K.N., Puran S., Koteshwara M., Manoj S., Santosh M., Chidambara J., Wishu S., Sumatha B. J. Chromatogr. B 2004, 809:243.
9. Zhu X., Xiao S., Chen B., Zhang F., Yao S., Wan Z., Yang D., Han H. J. Chromatogr. A 2005, 1066:89.
10. Subba Rao D.V., Radhakrishnanand P., Himabindu V. Chromatographia 2008, 67:183.
11. Aboul-Enein H.Y., Ali I. Talanta 2005, 65:276.
12. Rabbaa-Khabbaz L., Daoud R.A. J. Appl. Res. 2006, 6:170.
13. Shakya A.K., Abu-awwad A.N.A., Arafat T.A., Melhim M. J. Chromatogr. B 2007, 852:403.
14. Cheng C.L., Chou C.H. J. Chromatogr. B 2005, 822:278.
15. Ali I., Aboul-Enein H.Y. Chromatographia 2004, 60:187.
16. Madhavi A., Reddy G.S., Suryanarayana M.V., Naidu A. Chromatographia 2008, 67:633.
17. Zarghi A., Foroutan S.M., Shafaati A., Khoddam A. Chromatographia 2007, 66:747.
18. Tadalafil tablets, Material Safety Data Sheet (MSDS), Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, 2003.